Please find below the latest White Papers provided by agencies and companies within the healthcare and pharmaceutical industry. These are provided by external comoanies and are not approved of, checked or edited by PMLiVE or PMGroup Worldwide Ltd.
February 9, 2024 | White Papers and Resources |
Therapy Watch Pulmonary Arterial Hypertension (PAH) is launching in the US market, with expansion into other geographies including Europe in 2024.
Brought to you by Inizio
January 29, 2024 | White Papers and Resources |
Recruiting patients for clinical trials is one of pharma’s greatest challenges. Imagery is a great way to connect with people on an emotional level and …
Brought to you by Cuttsy + Cuttsy
January 25, 2024 | White Papers and Resources |
Clinical trial recruitment can be a challenge. By applying the principles of health literacy to all materials, we can support people to make an informed …
Brought to you by Cuttsy + Cuttsy
January 24, 2024 | White Papers and Resources |
Medical Writer, Tayyibah Ali looks at how we mentor excellence within our team
Brought to you by Mednet
January 22, 2024 | White Papers and Resources |
Learn how our client executed a series of 3 virtual touchpoints with 5 rare disease patient advocates to:- Develop a better understanding of the current …
Brought to you by Impetus Digital
January 16, 2024 | White Papers and Resources |
By Frank Fisher
Brought to you by Amiculum
January 15, 2024 | White Papers and Resources |
Join us for a look at the top-5 emerging virtual collaboration trends…
Brought to you by Impetus Digital
January 15, 2024 | White Papers and Resources |
Explore the key areas to include in a Medical Affairs strategy and plan that is fit for the future in our latest whitepaper.
Brought to you by OPEN Health
January 12, 2024 | White Papers and Resources |
We take a look at why the words we use in medcomms matter and examine the use of patient-first language
Brought to you by Mednet
January 5, 2024 | White Papers and Resources |
Although orphan drugs represent a sizeable portion of new drug approvals, most rare diseases still lack effective treatment. Even more so than for other conditions, rare …
Brought to you by Impetus Digital